174 related articles for article (PubMed ID: 38580331)
21. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD 40 monoclonal antibody.
Geldart T; Illidge T
Leuk Lymphoma; 2005 Aug; 46(8):1105-13. PubMed ID: 16085550
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
24. Fibronectin fibrils regulate TGF-β1-induced Epithelial-Mesenchymal Transition.
Griggs LA; Hassan NT; Malik RS; Griffin BP; Martinez BA; Elmore LW; Lemmon CA
Matrix Biol; 2017 Jul; 60-61():157-175. PubMed ID: 28109697
[TBL] [Abstract][Full Text] [Related]
25. Antibody-based immunotherapy of cancer.
Weiner LM; Murray JC; Shuptrine CW
Cell; 2012 Mar; 148(6):1081-4. PubMed ID: 22424219
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
27. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
[TBL] [Abstract][Full Text] [Related]
28. The promise and challenges of immune agonist antibody development in cancer.
Mayes PA; Hance KW; Hoos A
Nat Rev Drug Discov; 2018 Jul; 17(7):509-527. PubMed ID: 29904196
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.
Ricciardi M; Zanotto M; Malpeli G; Bassi G; Perbellini O; Chilosi M; Bifari F; Krampera M
Br J Cancer; 2015 Mar; 112(6):1067-75. PubMed ID: 25668006
[TBL] [Abstract][Full Text] [Related]
30. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
31. Blocking Netrin-1 Slows Cancer Progression.
Cancer Discov; 2023 Oct; 13(10):OF4. PubMed ID: 37594250
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
Stalin J; Traboulsi W; Vivancos-Stalin L; Nollet M; Joshkon A; Bachelier R; Guillet B; Lacroix R; Foucault-Bertaud A; Leroyer AS; Dignat-George F; Bardin N; Blot-Chabaud M
Int J Cancer; 2020 Sep; 147(6):1666-1679. PubMed ID: 32022257
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies in cancer immunotherapy.
Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C
Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129
[TBL] [Abstract][Full Text] [Related]
34. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.
Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
Mol Oncol; 2014 May; 8(3):565-80. PubMed ID: 24508063
[TBL] [Abstract][Full Text] [Related]
35. Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin.
Ding Y; Gelfenbeyn K; Freire-de-Lima L; Handa K; Hakomori SI
FEBS Lett; 2012 Jun; 586(13):1813-20. PubMed ID: 22641031
[TBL] [Abstract][Full Text] [Related]
36. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Queralt B; Báez L; Guardeño R; Hernández-Yagüe X; Martin-Castillo B; Brunet J; Menendez JA
J Cell Biochem; 2011 Jan; 112(1):10-29. PubMed ID: 21104905
[TBL] [Abstract][Full Text] [Related]
37. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
[TBL] [Abstract][Full Text] [Related]
38. Expression of netrin-1 by hypoxia contributes to the invasion and migration of prostate carcinoma cells by regulating YAP activity.
Chen H; Chen Q; Luo Q
Exp Cell Res; 2016 Dec; 349(2):302-309. PubMed ID: 27815019
[TBL] [Abstract][Full Text] [Related]
39. Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.
Chockley PJ; Keshamouni VG
J Immunol; 2016 Aug; 197(3):691-8. PubMed ID: 27431984
[TBL] [Abstract][Full Text] [Related]
40. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
